Physician profile
Julia M Kwan
NPI 1225194103
$8,994.21
in general payments reported to CMS, 2019-2025
29 companies · $2,050 in 2025
The $2,050 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2021: $91.95 · 2022: $1,360 · 2023: $2,034 · 2024: $2,017 · 2025: $2,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,899 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,899.07 |
| Education | $201.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,416.23 | 2019-2025 | |
| Janssen Biotech, INC. | $858.44 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $670.50 | 2022-2025 | Opzelura |
| Pfizer INC. | $620.54 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $595.85 | 2022-2024 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $557.40 | 2019-2025 | Absorica Ld, Winlevi |
| Genzyme Corporation | $519.20 | 2021-2025 | |
| Ucb, INC. | $498.66 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $447.47 | 2019-2025 | |
| Amgen INC. | $426.63 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $384.05 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $308.50 | 2023-2025 | Nemluvio, Aklief, Twyneo |
| Teladoc Health, INC. | $300.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $242.43 | 2019-2025 | Cabtreo, Jublia |
| Leo Pharma INC. | $242.14 | 2022-2025 | Adbry |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $216.09 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $138.69 | 2022-2024 | Sotyktu |
| Dermira, INC. | $125.00 | 2019 | |
| Arcutis Biotherapeutics, INC. | $115.31 | 2024-2025 | Zoryve |
| Almirall LLC | $49.56 | 2022-2025 | Klisyri |
| Biofrontera INC. | $41.77 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $34.83 | 2025 | Vtama |
| Sebela Pharmaceuticals INC. | $33.37 | 2023 | Naftin |
| Ani Pharmaceuticals, INC. | $30.91 | 2025 | Purified Cortrophin Gel |
| Botanix Sb INC | $25.72 | 2025 | Sofdra |
| Smith+Nephew, INC. | $24.83 | 2024 | Regranex, Collagenase Santyl |
| Lnhc, INC | $24.00 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.58 | 2022 | |
| Blueprint Medicines Corporation | $22.51 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Kwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.